Yes, Incruse Ellipta is taken once daily
Incruse Ellipta (umeclidinium 62.5 mcg) is administered as one inhalation once daily for the maintenance treatment of COPD. 1
Dosing Specifications
The FDA-approved dosing regimen is straightforward:
- One actuation (62.5 mcg umeclidinium) once daily by oral inhalation 1
- Must be used at the same time every day 1
- Do not use more than once every 24 hours 1
No Dose Adjustments Required
The prescribing information explicitly states that no dosage adjustment is necessary for:
- Geriatric patients
- Patients with renal impairment
- Patients with moderate hepatic impairment 1
Evidence Supporting Once-Daily Dosing
The once-daily dosing schedule is supported by dose-response pharmacology studies demonstrating that:
- Umeclidinium doses ≥62.5 mcg once daily were superior to lower doses 2
- Twice-daily dosing provided no additional benefit over once-daily administration 2
- The potency estimate (ED50) was 33 mcg with once-daily dosing, supporting the 62.5 mcg dose selection 2
Clinical Context
As a long-acting muscarinic antagonist (LAMA), umeclidinium fits into COPD management guidelines 3 as a maintenance bronchodilator. The once-daily dosing enhances adherence compared to multiple-daily-dose regimens, which is particularly important for chronic disease management.
Common pitfall to avoid: Do not use Incruse Ellipta for acute symptom relief or rescue therapy—it is not indicated for acute bronchospasm and should not be used more frequently than once daily even during symptom worsening 1.